Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry

The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line therapy for PsA.Objective: to study the rate of MDA...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina
Μορφή:	Artigo
Γλώσσα:	Russo
Έκδοση:	IMA-PRESS LLC 2021-02-01
Σειρά:	Современная ревматология
Θέματα:	psoriatic arthritis minimal disease activity synthetic disease-modifying antirheumatic drugs methotrexate
Διαθέσιμο Online:	https://mrj.ima-press.net/mrj/article/view/1096
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!